Vicore Pharma Holding AB (publ) (VICO.ST)

SEK 7.77

(1.17%)

Total Debt Summary of Vicore Pharma Holding AB (publ)

  • Vicore Pharma Holding AB (publ)'s latest annual total debt in 2023 was - SEK , down -100.0% from previous year.
  • Vicore Pharma Holding AB (publ)'s latest quarterly total debt in 2024 Q2 was - SEK , down -100.0% from previous quarter.
  • Vicore Pharma Holding AB (publ) reported annual total debt of 65 Thousand SEK in 2022, down -79.69% from previous year.
  • Vicore Pharma Holding AB (publ) reported annual total debt of 320 Thousand SEK in 2021, up 128.57% from previous year.
  • Vicore Pharma Holding AB (publ) reported quarterly total debt of - SEK for 2024 Q2, down -100.0% from previous quarter.
  • Vicore Pharma Holding AB (publ) reported quarterly total debt of - SEK for 2023 FY, down -100.0% from previous quarter.

Annual Total Debt Chart of Vicore Pharma Holding AB (publ) (2023 - 2012)

Historical Annual Total Debt of Vicore Pharma Holding AB (publ) (2023 - 2012)

Year Total Debt Total Debt Growth
2023 - SEK -100.0%
2022 65 Thousand SEK -79.69%
2021 320 Thousand SEK 128.57%
2020 140 Thousand SEK -26.32%
2019 190 Thousand SEK 0.0%
2018 - SEK 0.0%
2017 - SEK 0.0%
2016 - SEK 0.0%
2015 - SEK -100.0%
2014 1.5 Million SEK -78.87%
2013 7.1 Million SEK 0.0%
2012 - SEK 0.0%

Peer Total Debt Comparison of Vicore Pharma Holding AB (publ)

Name Total Debt Total Debt Difference
Alligator Bioscience AB (publ) 16.09 Million SEK 100.0%
Ziccum AB (publ) 857 Thousand SEK 100.0%
Modus Therapeutics Holding AB (publ) - SEK NaN%
BioArctic AB (publ) 4.97 Million SEK 100.0%
Sprint Bioscience AB (publ) - SEK NaN%
Mendus AB (publ) 24.48 Million SEK 100.0%
Genovis AB (publ.) 79.32 Million SEK 100.0%
Intervacc AB (publ) 181 Thousand SEK 100.0%
QuiaPEG Pharmaceuticals Holding AB (publ) 20.61 Million SEK 100.0%
Active Biotech AB (publ) 3 Million SEK 100.0%
Magle Chemoswed Holding AB (publ) 60.3 Million SEK 100.0%
Bio-Works Technologies AB (publ) - SEK NaN%
Aptahem AB (publ) 5 Million SEK 100.0%
Kancera AB (publ) - SEK NaN%
Infant Bacterial Therapeutics AB (publ) - SEK NaN%
Fluicell AB (publ) - SEK NaN%
Saniona AB (publ) 71.4 Million SEK 100.0%
Lipigon Pharmaceuticals AB (publ) - SEK NaN%
Biovica International AB (publ) 7.82 Million SEK 100.0%
Spago Nanomedical AB (publ) - SEK NaN%
AcouSort AB (publ) - SEK NaN%
Xintela AB (publ) - SEK NaN%
Abliva AB (publ) 424 Thousand SEK 100.0%
Egetis Therapeutics AB (publ) 108.6 Million SEK 100.0%
Karolinska Development AB (publ) 3.07 Million SEK 100.0%
OncoZenge AB (publ) - SEK NaN%
Amniotics AB (publ) 2.58 Million SEK 100.0%
2cureX AB (publ) - SEK NaN%
CombiGene AB (publ) - SEK NaN%
Asarina Pharma AB (publ) 1 Million SEK 100.0%
Calliditas Therapeutics AB (publ) 979.13 Million SEK 100.0%
Camurus AB (publ) 24.5 Million SEK 100.0%
Corline Biomedical AB - SEK NaN%
IRLAB Therapeutics AB (publ) 27.56 Million SEK 100.0%
Isofol Medical AB (publ) - SEK NaN%
I-Tech AB - SEK NaN%
Hansa Biopharma AB (publ) 866.76 Million SEK 100.0%
Cyxone AB (publ) 858 Thousand SEK 100.0%
ExpreS2ion Biotech Holding AB (publ) 1.71 Million SEK 100.0%
Biosergen AB - SEK NaN%
Cantargia AB (publ) - SEK NaN%
NextCell Pharma AB - SEK NaN%
Xspray Pharma AB (publ) 36.8 Million SEK 100.0%
Elicera Therapeutics AB (publ) - SEK NaN%
Nanologica AB (publ) 666 Thousand SEK 100.0%
SynAct Pharma AB 637 Thousand SEK 100.0%
Annexin Pharmaceuticals AB (publ) - SEK NaN%
Stayble Therapeutics AB (publ) 850 Thousand SEK 100.0%
LIDDS AB (publ) - SEK NaN%
Lipum AB (publ) 1.76 Million SEK 100.0%
BioInvent International AB (publ) 23.24 Million SEK 100.0%
Alzinova AB (publ) 800 Thousand SEK 100.0%
Oncopeptides AB (publ) 106.48 Million SEK 100.0%
Pila Pharma AB (publ) 773.08 Thousand SEK 100.0%
Guard Therapeutics International AB (publ) - SEK NaN%
Scandinavian ChemoTech AB (publ) - SEK NaN%
Simris Alg AB (publ) 90.74 Million SEK 100.0%
Diamyd Medical AB (publ) 30.67 Million SEK 100.0%
Xbrane Biopharma AB (publ) 231.47 Million SEK 100.0%
Ascelia Pharma AB (publ) 1.06 Million SEK 100.0%
Diagonal Bio AB (publ) - SEK NaN%